Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors

Inclusion Criteria: * Age 18 and above, regardless of gender; * Histopathological diagnosis with non-functional pancreatic neuroendocrine tumor, pancreatic ductal adenocarcinoma or solid pseudopapillary tumor; * Not receiving any anti-tumor treatment before surgery, including chemotherapy, embolization, ablation, radiotherapy, and molecular targeted therapy; * No obvious surgical contraindications; * Able to comply with research plans, follow-up plans, and other protocol requirements; * Voluntary participation and signed informed consent. Exclusion Criteria: * Pathological diagnosis was not pancreatic neuroendocrine tumor, pancreatic ductal adenocarcinoma or solid pseudopapillary tumor; * Currently diagnosed with other types of tumors or any cancer history; * Diagnosed with familial syndromes; * Receiving anti-tumor treatment before surgery, including chemotherapy, embolization, ablation, radiotherapy, and molecular targeted therapy; * Ongoing fever or recipient of anti-inflammation therapy within 14 days prior to study blood draw; * Recipient of blood transfusion within 30 days prior to study blood draw; * Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant; * Poor health condition and not suitable for blood draw; * Any other disease/condition deemed not suitable for study enrollment by researcher.